High risk non-muscle invasive bladder cancer: From guidelines to future approaches Chairs: A. Lopez Beltran, Lisbon (PT)

Transcription

1 Friday, 8 June 2018 EAU Update on Bladder Cancer (BCa18) Challenging your knowledge of the EAU Guidelines 8-9 June 2018, Munich, Germany Steering committee: F. Montorsi, H. Van Poppel and M. Wirth Scientific committee: A. Necchi, J. Palou, T. Powles and A. Stenzl Introduction and format of the meeting High risk non-muscle invasive bladder cancer: From guidelines to future approaches Chairs: A. Lopez Beltran, Lisbon (PT) S. Shariat, Vienna (AT) EAU and ESMO Guidelines on Non-Muscle Invasive Bladder Cancer (NMIBC). What s new and what needs to be changed WHO 2016 classification R. Montironi, Ancona (IT) Immunotherapy in non-muscle invasive urothelial bladder cancer: Towards a new multidisciplinary paradigm? A. Kamat, Houston (US) Discussion Case discussion 1 (Interactive voting session) Faculty group 1: How to optimise TURBT? Speakers: P. Gontero, Turin (IT) F. Witjes, Nijmegen (NL) Faculty group 2: Bladder instillations: When and how? Speakers: P. Chlosta, Cracow (PL) Faculty group 3: Early cystectomy for NMIBC: Indications for patient selection Speakers: A. Kamat, Houston (US) M. Roupret, Paris (FR)

2 Faculty group 1 room Coffee break Faculty group 2 room Faculty group 3 room Lunch Muscle invasive and advanced bladder cancer: Surgical and systemic approaches Chairs: M. Colombel, Lyon (FR) EAU and ESMO Guidelines on Muscle Invasive Bladder Cancer (MIBC). What s new and what needs to be changed J. Bellmunt, Boston (US) New drugs and therapeutic sequences in locally-advanced stages Case discussion 2 (Interactive voting session) Faculty group 1: Neoadjuvant and adjuvant therapy: Current indications, trials, and patient selection Speakers: Faculty group 2: Technical aspects of open radical cystectomy Speakers: H. Van Poppel, Leuven (BE) Faculty group 3: Radical cystectomy: Indications and tricks for the robotic approach Speakers: M. Gallucci, Rome (IT) F. D Hont, Aalst (BE)

3 Faculty group 1 room Faculty group 2 room Coffee break Faculty group 3 room 2 Saturday, 9 June What is new in bladder cancer classification and treatment? Chairs: J. Bellmunt, Boston (US) R. Montironi, Ancona (IT) M. Roupret, Paris (FR) The shifting landscape of molecular classification: The impact of Genomics in clinical practice S. Lerner, Houston (US) Immunotherapy for metastatic bladder cancer: PD-1/PD-L1 pathway and clinical implications Unresectable tumours: Palliative management of Muscle Invasive Bladder Cancer (MIBC) and role of surgery postchemotherapy M. Brausi, Modena (IT) Discussion Case discussion 3 (Interactive voting session) Faculty group 1: Histological variants in bladder cancer: How to deal with them? Speakers: S. Lerner, Houston (US) S. Shariat, Vienna (AT)

4 Faculty group 2: Palliative cystectomy: Indications and patient selection Speakers: M. Ribal, Barcelona (ES) Faculty group 3: Management of metastatic bladder cancer Speakers: J. Bellmunt, Boston (US) Faculty group 1 room Coffee break Faculty group 2 room Faculty group 3 room Lunch Novel biomarkers and drug combinations for urothelial cancer Postoperative management of surgical patients Chairs: P. Gontero, Turin (IT) A. Karl, Munich (DE) Enhanced recovery after radical cystectomy (ERAS) and immunonutrition in bladder cancer patients J. Catto, Sheffield (GB) Sexual and urinary rehabilitation after bladder cancer A. Briganti, Milan (IT) Discussion Case discussion 4 (Interactive voting session) Faculty group 1: Radical cystectomy: How to optimise peri and postoperative management and manage complications Speakers: J. Catto, Sheffield (GB) J. Kelly, London (GB)

5 Faculty group 2: Bladder sparing in Muscle Invasive Bladder Cancer (MIBC): Selection and optimal treatment Speakers: A. Choudhury, Manchester (GB) V. Fonteyne, Ghent (BE) Close